OncoMatch/Clinical Trials/NCT06893783
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
Is NCT06893783 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tarlatamab for neuroendocrine carcinomas (nec).
Treatment: Tarlatamab — This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received platinum-based first-line chemotherapy. Participants will receive tarlatamab on Cycle 1 Day 1 (C1D1), Day 8 (C1D8), and Day 15 (C1D15), followed by administration every two weeks thereafter. No placebo control is included in this study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Neuroendocrine Tumor
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line (except prostate cancer, where platinum may be later line)
Subject has progressed or recurred following 1 platinum-based regimen: documented first disease progression must be during or following first-line platinum-based systemic chemotherapy. For patients with prostate cancer, especially in cases with treatment-emergent neuroendocrine carcinoma, platinum-based chemotherapy will not need to be the first line therapy.
Cannot have received: tarlatamab
Prior therapy with tarlatamab
Cannot have received: DLL3 pathway inhibitor
Prior therapy with any selective inhibitor of the DLL3 pathway
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9 /L; Platelet count ≥ 100 x 10^9/L; Hemoglobin > 9 g/dL (90 g/L)
Kidney function
eGFR ≥ 30 mL/min/1.73 m^2 or creatinine clearance ≥ 30 mL/min
Liver function
AST and ALT < 3 x ULN (or <5 x ULN for subjects with liver involvement); total bilirubin <1.5 x ULN (<2 x ULN for subjects with liver involvement) (except participants with Gilbert syndrome who must have total bilirubin <3.0 mg/dL)
Cardiac function
Cardiac ejection fraction ≥50%, no clinically significant pericardial effusion as determined by ECHO or MUGA, and no clinically significant ECG findings
Adequate organ function, defined as follows: Hematological function: Absolute neutrophil count ≥ 1.5 x 10^9 /L Platelet count ≥ 100 x 10^9/L Hemoglobin > 9 g/dL (90 g/L); Coagulation function: PT/INR and PTT or aPTT ≤ 1.5 x ULN except for subjects undergoing new class anticoagulant therapy (eg, Edoxaban), stable dose for 2 weeks required prior to enrollment; Renal function: eGFR ≥ 30 mL/min/1.73 m^2 or creatinine clearance ≥ 30 mL/min; Hepatic function: AST and ALT < 3 x ULN (or <5 x ULN for subjects with liver involvement) total bilirubin <1.5 x ULN (<2 x ULN for subjects with liver involvement) (except participants with Gilbert syndrome who must have total bilirubin <3.0 mg/dL); Pulmonary function: no clinically significant pleural effusion. Pleural effusion managed with indwelling pleural catheter (eg, PleurX) are allowed baseline oxygen saturation >90% on room air; Cardiac function: cardiac ejection fraction ≥50%, no clinically significant pericardial effusion as determined by an echocardiogram (ECHO) or multigated acquisition (MUGA) scan, and no clinically significant electrocardiogram (ECG) findings
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06893783 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior tarlatamab, DLL3 pathway inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages